FreseniusKabi Oncology is trading lower by 3% at Rs 102 after the pharmaceutical company said it has received a warning letter from the US health regulator asking for certain other information and implementation of more corrective and preventive measures regarding GMP non- conformities.
"The company has received a warning letter from US Food and Drug Administration (USFDA), inter-alia, asking for certain other information and implementation of more corrective and preventive measures so as to avoid recurrence of deviations," Fresenius Kabi Oncology said in a BSE filing.
On February 26, during a routine inspection at the company's API plant located at Kalyani, West Bengal, USFDA had made observations relating to GMP non-conformities in respect of manufacturing, documentation practises and product testing, it added.
The stock opened at Rs 109 and hit a low of Rs 102 on BSE. A combined around 8,000 shares have changed hands on the counter in early morning deals on BSE and NSE.
"The company has received a warning letter from US Food and Drug Administration (USFDA), inter-alia, asking for certain other information and implementation of more corrective and preventive measures so as to avoid recurrence of deviations," Fresenius Kabi Oncology said in a BSE filing.
On February 26, during a routine inspection at the company's API plant located at Kalyani, West Bengal, USFDA had made observations relating to GMP non-conformities in respect of manufacturing, documentation practises and product testing, it added.
The stock opened at Rs 109 and hit a low of Rs 102 on BSE. A combined around 8,000 shares have changed hands on the counter in early morning deals on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%